Table 2: Correlations between levels of NEP, ET-1, NFκB expression, and clinicopathological characteristics.

CharacteristicNEP ET-1 NFκB
lowhighlowhighlowhigh
(%) (%) (%) (%) (%) (%)

Pre-op PSA
 <1028 (96.6)34 (82.9)0.07632 (94.1)30 (83.3)0.27735 (83.3)27 (96.4)0.191
 ≥101 (3.4)7 (17.1)2 (5.9)6 (16.7)7 (16.7)1 (3.6)
Gleason score
 ≤7 (3 + 4)20 (55.6)30 (88.2)0.00319 (55.9)31 (86.1)0.00837 (74)6 (30)0.001
 ≥7 (4 + 3)16 (44.4)4 (11.8)15 (44.1)5 (13.9)13 (26)14 (70)
pT stage
 ≤217 (47.2)25 (73.5)0.03014 (41.2)28 (77.8)0.00332 (76.2)11 (39.3)0.003
 ≥319 (52.8)9 (26.5)20 (58.8)8 (22.2)10 (23.8)17 (60.7)
SMs
  (−)22 (61.1)27 (79.4)0.12120 (58.8)29 (80.6)0.06833 (76.7)16 (59.3)0.180
  (+)14 (38.9)7 (20.6)14 (41.2)7 (19.4)10 (23.3)11 (40.7)

Pre-op PSA: preoperative PSA; pT stage: pathologic TNM stage; SMs: surgical margins; number of patients; statistical value.